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Persistent infection with high-risk HPV is the etiologic agent associated with the development of cervical cancer (CC) develop-
ment. However, environmental, social, epidemiological, genetic, and host factors may have a joint inﬂuence on the risk of disease
progression. Cervical lesions caused by HPV infection can be removed naturally by the host immune response and only a small
percentagemayprogresstocancer;thus,theimmuneresponseisessentialforthecontrolofprecursorlesionsandCC.Wepresenta
review of recent research on the molecular mechanisms that allow HPV-infected cells to evade immune surveillance and potential
targets of molecular therapy to inhibit tumor immune escape.
1.Introduction
Infection with oncogenic types of human papillomavirus
(HPV) is the main etiologic factor in cervical cancer (CC)
and in its precursor, neoplasia. CC can be a model system
forstudyingtheinteractionsbetweencellstransformedbyan
oncogenicagentandtheimmunesystem,duringtheprogres-
sion of the squamous intraepithelial lesion (SIL) [1].
The majority of women clear HPV infection spontane-
ously by the host immune response, but persistence of HPV
infection has been suggested to be associated with devel-
opment of SIL [2]. The fact that only a small proportion
of HPV-infected individuals will eventually develop cancer
of the cervix and the long latency period between primary
infections and cancer emergence suggest that additional
factors are involved in the progression. Other factors such as
genetic susceptibility or alteration of the immune response
increase the incidence of HPV-associated lesions. A substan-
tial majority of SILs and cancers develop within a speciﬁc
region of the cervix, the transformation zone, implying
that other exogenous or endogenous factors speciﬁc to the
anatomical milieu may be conducive to SIL and cancer
development [3].
A great number of tumors have been identiﬁed in
humans, most of them growing after the reproductive age.
Somatic mutations allow some antigenic tumors to evade the
immune response, to grow successfully and persist in our
organism in spite of a functionally adequate immune system.
Theimmunologyoftumorsassociatedwithinfectiousagents
isaremnantofimmuneresponseagainstexternalpathogens,
and low levels of infectious agents can coexist with T-cell-
mediatedimmunity;asaresult,theimmunesystemisunable
to eliminate all infected cells [4].
In this paper, we review the mechanisms that allow
CC cells to evade immune surveillance and the molecu-
lar therapy to inhibit tumor immune escape. The tumor
immune escape refers to the mechanism by which the
body maximizes immune tolerance, through the production
of soluble immunosuppressive factors (Interleukin (IL)-
10, transforming growth factor-beta1 (TGF-β1), tumor-
inﬁltrating cells such as macrophages and granulocytes),
and the recruitment of suppressive cells of the adaptive and
innate immune system.2 Journal of Oncology
2. CervicalCancerMolecular Mechanism
2.1. Cellular Immune Response in Cervical Cancer. Tumor
immunity in CC is activated by helper T cell type 1 (Th1)
cytokines and inhibited by Th2 cytokines. Several cytokines
have been shown to contribute to the initiation or suppres-
sion of cellular immune responses, such as IL-4, IL-12, IL-
10, and/or TGF-β1, produced by various cell types, including
macrophages, dendritic cells, and keratinocytes [5].
As an approach to understanding the factors involved in
the generation and maintenance of an eﬃcient antitumor
response in CC, several research groups have examined the
local expression proﬁle of Th1, Th2, and Th3 cytokines in
HPV-positive CC biopsies. The data indicate that more than
80% of the tumors expressed low levels of CD4 mRNA,
with all of them expressing higher CD8 mRNA levels. Most
tumors expressed IL-4 and IL-10 messenger RNA (mRNAs)
and, most importantly, all of them expressed TGF-β1a n d
interferon γ (IFN-γ) mRNA. None of the studied tumors
expressedIL-12,IL-6,ortumornecrosisfactor(TNF)mRNA
[5–15].
There are more tumor inﬁltrating T lymphocytes (TIL)
in the stroma than in epithelium, in biopsies from women
withSIL(includingacarcinomainsituandanormalregion),
and in advanced stages of the disease where CD8+ T cells
prevailed [7]. Consistent with other reports [8], it was found
that CD8+ T cells are predominant, compared to CD4+ T
cells, in women with CC. However, what are the mechanisms
behind this distribution as well as behind the inability of
these CD8+ T cells to eliminate the tumor in CC remains
unclear [7].
Immunohistochemical analysis identiﬁed IL-10 only in
tumor cells and koilocytic cells, but not in tumor-inﬁltrating
lymphocytes, suggesting that IL-10-producing cells are
those transformed by HPV. It was found a correlation
between immunostaining for IL-10 protein and the level
of IL-10 mRNA expression and supernatants from HPV-
transformed cell lines containing IL-10 and TGF-β1. These
ﬁndings show a predominant expression of immunosup-
pressive cytokines, which help to downregulate tumor-
speciﬁc immune responses in the tumor microenvironment
[6, 10]. Furthermore, using an experimental murine model,
it has been demonstrated that HPV16 tumors are not only
inﬁltratedbylargenumbersofM2-like macrophages(TAM),
but there is an expansion of myeloid cells in the spleen and
altered T/B lymphocyte ratio in the peripheral lymph nodes
of tumor bearing mice, indicating systemic eﬀects initiated
by the tumors. It has been shown that TAM and myeloid
populations in the spleen of HPV16 tumor-bearing mice
are important for tumor growth via stimulation of speciﬁc
regulatory T cells, in a mechanism partially dependent on
IL-10 expression by TAM [16, 17]. Furthermore, in C3
tumor-bearing mice, Gr-1(+) cells completely blocked T-cell
response to a peptide presented by major histocompatibility
complexclassI(MHCclassI)invitroandinvivo.Blockingof
the speciﬁc MHC class I molecules on the surface of Gr-1(+)
cells completely abrogated the observed eﬀects of these cells.
Thus, immature myeloid cells speciﬁcally inhibited CD8-
mediated Ag-speciﬁc T-cell response, but not CD4-mediated
T-cell response [18]. This represents a mechanism of cellular
immune response inhibition, as a potential therapeutic
alternative.
Previous studies have suggested that a reduced T cell
function can be associated with alterations in CD3ζ protein
expression [8]. Thus, the CD3ζ mRNA expression by T cells
has been examined as an indicator of possibly decreased
T-cell function in CC patients. CC progression has been
associated with lower CD3ζ mRNA, which was even lower
in TIL. Studies were done to determine whether decreased
CD3ζ mRNA expression correlated with low T-cell prolifer-
ation in CC. As expected, there was a signiﬁcant correlation
between low T-cell proliferation and decreased CD3ζ mRNA
expression by anti-CD3 stimulated T cells. Thus, decreased
T-cell function appears to correlate with CC progression,
which is in agreement with a decreased T-cell proliferation
in CC patients [7].
To establish the possible association of cytokines with
levels of CD3ζ expression, we evaluated the relationship
between a number of cytokines and CD3ζ expression by
PBL and PBL versus TIL. As expected, there were signiﬁcant
positive associations between CD3ζ/IL-2 and CD3ζ/IFN-γ
mRNA expression. Moreover, there was an inverse associa-
tion for IL-10/CD3ζ mRNA expression in PBL. These results
show that an optimal expression of CD3ζ is associated with
expression of IL-2 and IFN-γ [7]. Furthermore, it has been
demonstrated that in vivo suppression of CD3ζ chains in
patients with CIN can be the result of a circulating factor
[15]. We believe that this circulating factor is composed of
IL-10 and TGF-β1 that reduce CD3ζ expression [7].
2.2. Tumor Immune Evasion in Cervical Cancer. Persistent
infection is a prerequisite, but may not be suﬃcient for
progressingtoCC.HPV“stealth”andimmuneevasivemech-
anisms enable infection to persist [19]. Several conditions
are required to establish HPV infection among others: the
viral lifecycle occurs within the epithelium, there is no
viremia, no cell death, and no inﬂammation, and a local
immunosuppression caused by HPV proteins is present.
This immunosuppressive state is characterized by repression
of TLR9 signal pathways by E6/E7, inﬂuence on IFN-γ
expression by E6/E7, inﬂuence on interferon-dependent
signal pathways by E6/E7, induction of TGF-β1 expression
by E6/E7, induction of IL-10 expression by E2 protein, and
reduction of migration of Langerhans cells (reduction of
E-cadherin by E6) [20–22]. It has been suggested that to
optimize immunotherapy strategies, correction of immune-
activating signals, eradication of inhibitory factors, and
the evasion of newly developed immunoresistant tumor
phenotypes need to be simultaneously considered [23].
3. PotentialTargets for Blocking HPV-Induced
Lesion Development
3.1. HPV E2 Protein as a Potential Therapeutic Target. The
E2 protein of papillomavirus is a regulatory protein playing
crucial roles during the vegetative viral cycle [24]. In HPV-
infected cells, the binding to the LCR is thought to repressJournal of Oncology 3
HPV gene expression, and E2 contributes to the control
of cell proliferation by regulating the expression of E6/E7.
However, in cervical carcinomas, the HPV genome often
becomes integrated into the host genome, resulting in loss
of E2 expression [25]. This leads to increased levels of
E6/E7and,asaconsequence,increasedcellproliferationand,
presumably, increased tumourigenesis. Moreover, HPV E2
protein possesses antiproliferative eﬀects when the HPV E2
gene is re-introduced experimentally into HPV-transformed
cells [26–29]. Ectopic expression of E2 from HPV 16, 18,
and bovine papillomavirus type 1 induces cell cycle arrest,
increases cell senescence, and strongly inhibits cell prolifera-
tion and increased apoptosis [26, 30–32]. The induction of
G1 growth arrest by HPV 18 E2 protein in HeLa cells it has
been associated with the E6/E7 oncogenes repression, which
induces stabilization of p53 [29]. In addition, the induction
of apoptosis by HPV E2 is shown in many HPV-negative
carcinoma cell lines, such as C33 A (cervical cancer), MCF7
(breast cancer), Saos-2 (osteosarcoma). Furthermore, E2-
mediated apoptosis is not speciﬁc to transformed cells as it
also occurs in primary epithelial cells [31, 33, 34].
These results show that the proapoptotic activity of E2 is
independentofotherviralfunctions,andmorespeciﬁcallyof
the transcriptional repression of the E6/E7 viral oncogenes.
T h i sa c t i v i t ya p p e a r sa sa na u t o n o m o u sf u n c t i o nb yw h i c h
the E2 protein can directly modify cell physiology. So the
HPV E2 will be a potential therapeutic toll to repress the
E6/E7 oncogenes, inducing inhibition of cell proliferation
and cell death by apoptosis in cervical cells.
In addition to its proapoptotic activity, HPV 16 E2 pro-
tein possesses antitumor eﬀects in nude mice bearing tumors
generated by inoculation of human HPV-transformed cell
lines [35, 36]. Immunization of animals with a recombinant
vaccinia virus containing the papillomavirus E2 protein
promotes tumor regression and decreases the number of
new papilloma that are formed [37]. On the other hand, the
administration of an adenovirus HPV 16 E2 recombinant
hadantitumoreﬀectsonanexperimentaltumorinimmuno-
competent mice inoculated with the BMK-16/myc (murine
cell line transformed with HPV16), indicating antitumor
eﬀects of the HPV 16 E2 [38]. These results highlight
the clinically relevant therapeutic targets derived from the
possible use of the HPV E2 protein for the prevention and
treatment of HPV-associated cancer.
3.2. Cytokine-Based Therapies in an Immunosuppressive State
in Cervical Cancer. The study of immune conditions per-
missive to tumor regression is a component of a broad
strategy aimed at the identiﬁcation of more eﬀective ther-
apeutic strategies. The cytokines that are produced in the
tumour microenvironment have an important role in cancer
pathogenesis.Cytokinesarereleasedinresponsetoinfection;
inﬂammation and immunity can function to inhibit tumour
development and progression. Alternatively, cancer cells can
respond to host-derived cytokines that promote growth,
attenuate apoptosis and facilitate invasion and metastasis. A
more detailed understanding of cytokine tumour cell inter-
actions provides new opportunities for improving cancer
immunotherapy [39].
In cervical tissue with HPV infection, anti-inﬂammatory
and immunosuppressive cytokines are expressed in the
cervical microenvironment, determining the persistence of
HPV and tumor progression by subverting cellular immune
surveillance mechanisms the shift is a secondary eﬀect
induced by the tumor cells, or may be due to the persistence
of the viral infection itself [12, 40]. Certain cytokines
(IL-4, IL-10, and TGF-β) are highly expressed locally in
biopsies from patients with premalignant lesions and CC,
and may have induced a local immunosuppression state.
In particular, IL-10 is highly expressed in tumor cells and
its expression is directly proportional to the development
of HPV-positive CC, suggesting an important role of HPV
proteins in the expression of IL-10 [6, 11]. The elevated
expression of IL-10 may allow for virus persistency, the
transformation of cervical epithelial cells, and consequently
cancer development. These ﬁndings may probably point
toward the potential usefulness of cytokine assays for deter-
mining prognosis or this lack of immune stimulation may
be overcome by enhancing the presentation of the tumor
antigens to T cells and by delivering immunostimulatory
cytokines [41].
Modiﬁcation of the immune response against cancer,
using speciﬁc cytokines, may prove eﬀective against cancers
such as CC [41]. Ofallcytokines tested inseveral experimen-
tal tumor models, IL-2 and IL-12 seem to have the strongest
antitumor activity [42]. IL-2 is a stronger stimulator of
proliferation and cytolytic activity that induces Th1-type
immune responses through inducing the maturation of
Th1 cells from uncommitted T-cell population. IL-12 is a
stronger inducer of IFN-γ from natural killer (NK) cells.
Furthermore, IL-12 was able to inhibit angiogenesis through
the IFN-inducible protein-10 [43]. Several studies have
reportedthatasaprotein,IL-12hasacriticalroleininducing
antiviral and antitumor eﬀects in vivo. Direct administration
by gene therapy cDNA expressing IL-12 or IL-12 protein
can aﬀect tumor progression and metastasis in animal
models [44–46]. In particular in CC, the direct intratumoral
injection of adenovirus expressing IL-12 (AdIL-12) resulted
in a signiﬁcant suppression of tumor growth in a CC animal
model system. The injection of AdIL-12 with E7 antigen
into either a tumor site or the distance site, along with
AdIL-12, further enhanced antitumor eﬀects signiﬁcantly,
more than AdIL-12 or E7 protein injection alone [47]. The
antitumor eﬀect of IL-12 was associated with enhancement
of IFN-γ levels and induction of antigen-speciﬁc CD8+ T-
cell response. In addition, the treatment with IL-12 gene has
been employed using nonviral gene therapy (naked DNA),
viral gene therapy [48]w i t ht h eu s eo fa d e n o v i r u s[ 47], ex
vivo gene therapy [49], and in combination with the E6/E7
oncogenes [48–50], as well as genes of immunomodulatory
molecules of the cellular immune response such as B7 [49].
Suppression of tumor growth was observed in all cases. IL-
12 is able to inhibit experimental metastasis formation and
is considered a good candidate for gene therapy against CC
[47]. Additionally, IL-12 gene therapy against CC has been
used in conjunction with other cytokines such as GM-CSF
and IL-2, resulting in an increase of the protective eﬀect
against tumor growth [51].4 Journal of Oncology
Additionally, a contribution to tumour progression in
CC,byimmunosuppressivecytokinessuchasIL-10,hasbeen
previously suggested [6, 11]. IL-10 is a Th2-type pleiotropic
cytokine that is produced at the tumour site and is increased
in sera of patients suﬀering from diﬀerent cancer types
[52]. IL-10 has been shown to hinder a number of immune
functions,forexampleT-lymphocyteproliferation,Th1-type
cytokine production, antigen presentation, and lymphokine-
activated killer cell cytotoxicity [10, 53]. One of the main
actions of this cytokine is its ability to inhibit the production
of proinﬂammatory cytokines, such as TNF-α,I L - 1 ,a n d
IL-12, which are synthesized by macrophages in response
to bacterial components, such as lipopolysaccharides (LPS)
[14]. This activity results in decreased IFN-γ production by
macrophages and Th1 lymphocytes and inhibition of cell-
mediated immune responses, while concomitantly enhanc-
inghumoralimmunity[50,54].Furthermore,IL-10strongly
reduces antigen-speciﬁc T-cell proliferation by inhibiting
the antigen-presenting capability of monocytes by down-
regulationoftheexpressionoftheirmajorhistocompatibility
complex class II (MHC-II) [55]. IL-10 is endowed with
multiple positive regulatory activities: it is a growth factor
for mature and immature T cells, it enhances the growth
and diﬀerentiation of CD28+ cytotoxic T lymphocytes
(CTLs), and it induces MHC-II expression in resting B cells,
sustaining their viability in vitro [56–58].
Since IL-10 has potent immunosuppressive and antiin-
ﬂammatory properties and is produced by some cancers, it
has been hypothesized that its production by tumor cells
may contribute to the escape from immune surveillance
[11]; however, the results obtained in in vivo models are
controversial.
The increase of tumour growth by IL-10 could be
inducedbyatleastthreediﬀerentsimultaneousmechanisms:
direct stimulation of cell proliferation through an autocrine
mechanism, induction of angiogenesis, and the suppression
of the local immune system.
Particularly in CC, immunosuppression is the main
mechanism proposed by which IL-10 could promote tumour
growth in human tumours and murine models [11, 59]. It
has been shown that IL-10 can be an autocrine growth factor
in culture cells [60] .Ap r e v i o u ss t u d yr e p o r t e dt h ee ﬀect of
I L - 1 0o nt u m o u rg r o w t hi nam o u s em e l a n o m am o d e la n d
the induction of cell proliferation, either through autocrine
stimulation of tumour cells or just through depression of
the immune system. To conﬁrm that the enhanced tumour
growth was exerted by IL-10 secretion, the tumour growth
of the highest IL-10-producer cells (B16-10) was explored
in mice treated with an IL-10-neutralizing antibody. In
these mice, the tumours grew slower than in control mice
and behaved in a similar way to those induced by non-
transfected tumour cells, conﬁrming that IL-10 secreted by
transfected cells is actually promoting the tumour growth
in a melanoma-B16 model. All the eﬀects induced by IL-
10 were prevented in mice treated with a neutralizing anti-
IL-10 monoclonal antibody. In several in vitro models,
IL-10 may inhibit diﬀerent immune mechanisms involved
in the antitumour response. However, in mouse models,
the eﬀect of IL-10 on the anti-tumour immune response
is controversial. In some models, IL-10 inhibits tumoral
growth by stimulation of the immune system, mostly of
CTLs and NK cells. In other models, the IL-10 promotes
the tumoral growth through a local immunosuppression,
inhibiting APC functions, CTLs, and the Th1 response. This
contradiction might be explained by diﬀerences in IL-10-
mediated outcomes due to concentration-dependent eﬀects.
In CC tumour models where IL-10 suppresses the immune
response and increases tumour growth, the production of
I L - 1 0i sm u c hl o w e r[ 61]. It is important to mention that
inhibition of IL-10 production by T cells or malignant
cells, using low-dose cyclophosphamide [62], anti-IL-10/IL-
10R-blocking antibodies [63, 64], or anti-IL-10 antisense
oligonucleotides [65], improves cancer-speciﬁc immune
responses in some preclinical tumor models, which leads
the authors to advocate the use of IL-10-neutralizing agents
as immunological adjuvants in the design of anticancer
vaccines [53].
3.3. MicroRNAs and Cervical Cancer. Knowledge about the
RNA interference (RNAi) mechanism has progressed con-
siderably and now we know that microRNAs are a new
familyofsmallendogenousRNAthathavediversesequences,
have independent tissue-speciﬁc and time-speciﬁc expres-
sion patterns, are evolutionarily conserved, and are impli-
cated in posttranscriptional regulatory mechanisms for the
silencing of the expression of sequence-speciﬁc genes [66–
68]. We know that most eukaryotic organisms have a great
number of genes that are transcribed as small RNA called
microRNA, which are natural eﬀector molecules of the RNAi
mechanism in eukaryotic cells [69]. MicroRNAs induce
their eﬀects at the mRNA level, by arresting the translation
or inducing the cleavage of target mRNA. The level at
whichthespeciﬁcmicroRNAandmRNAarecomplementary
deﬁnes which process will be carried out. The pathway
in which the nucleotides in microRNA and mRNA are
perfectly complementary induces cleavage of transcripts,
whilemismatchesbetweenseveralunpairedbasesproducean
arrest of translation [69]. Therefore, for the human species,
the relevance of gene expression silencing by RNAi will be
better understood when we know the molecular components
and the regulatory mechanisms of this process, in normal
physiological conditions as well as during the development
of pathologies that have gene expression disruption, such as
in the carcinogenesis process. Many eﬀorts have been made
to design new drugs and develop gene therapy to treat CC
[41]. Alternatively, it has been demonstrated that the RNAi
mechanism represses the expression of viral oncogenes at the
posttranscriptional level, by several orders of magnitude and
more eﬃciently than another treatments [70, 71]. Therefore,
knowledge of molecular events in gene expression silencing
by RNAi, and their applications during CC development,
are a real and eﬃcient gene therapy strategy against the
development of this neoplasia.
3.4. siRNAs for HPV E6 and E7 Oncogenes, as Potential Gene
Therapy for Cervical Cancer. RNAi may silence the expres-
sion of genes that encode for tumoral antigens or viralJournal of Oncology 5
oncogenes, in order to repress the speciﬁc proliferation of
cancerous cells. As a consequence, the silencing of genes by
RNAi is a potential mechanism to inactivate foreign DNA
sequences and a successful strategy to silence the expression
of HPV oncogenes in CC. The ﬁndings reported by several
groups in this kind of studies are summarized in Table 1.
The ﬁrst studies carried out with synthetic siRNA in
order to induce the silencing of HPV16 E6 and E7 oncogenes
expression were developed by Jiang and Milner in 2002
[72]. In this study, the authors showed the biological eﬀect
of siRNAs in human cells from cervical carcinoma. The
administration of siRNAs led to mRNA cleavage and the
speciﬁc silencing of HPV16 E6 and E7 oncogenes expression.
Besides this, E6 silencing induced the expression of gene p53,
transactivation of the inhibiting gene of p21-CIP1/WAF1
cyclin-kinase, and decrease of cellular proliferation, whereas
silencing of E7 induced cellular death by apoptosis. Thus, the
ﬁndings reported by this group demonstrated, for the ﬁrst
time, that the expression of HPV E6 and E7 oncogenes may
be speciﬁcally silenced by siRNAs in human tumoral cervical
cells that have been transformed by HPV.
3.5. Silencing of HPV E6 and E7 Bicistron with siRNAs.
Attention has been focused on an aspect of the use of siRNAs
for HPV E6/E7 oncogenes, which is their ability to silence
the HPV E6-E7 bicistron. The eﬀe c to fs y n t h e t i cs i R N A
for HPV16 E6 oncogene on SiHa cells (HPV16+) has been
reported and the silencing of both E6 and E7 oncogenes
has been observed [73]. In addition, observations have been
made as to the inhibition of cellular proliferation, p53
protein expression, the induction of p21-CIP1/WAF1 gene,
and the identiﬁcation of the cell cycle arrest mediator—the
hypophosphorylated form of pRb associates—as well as the
inactivation of E2F transcription factor. Furthermore, when
the SiHa cells were inoculated in immune deﬁcient (SCID)
mice and treated with siRNAs for E6 oncogene, a decrease
in the ability of cancerous cells to induce tumor formation in
the animals was detected. Therefore, the ﬁndings reported by
this group show that siRNAs for HPV16 E6 oncogene have
an eﬀect on the E6/E7 bicistron in vitro as well as in vivo.
Another group has reported the use of synthetic siRNAs for
H P V 1 8E 6o n c o g e n e[ 74]. In this study, the induction of
apoptosis of the CaSki cells (HPV16+), the increase of p53
and p21-CIP1/WAF1 expression, and the expression of the
hypophosphorylated isoform of pRb were demonstrated. A
ﬁndingthatwasnoteworthyinthisstudywasthatsiRNAsfor
HPV18 E6 did not aﬀect HPV18 E7 expression. Initially, this
observation seems to contradict what was reported by Jiang
etal.,whodemonstrated thatsiRNAsforE6oncogenhavean
eﬀe c to nb o t hE 6a n dE 7o n c o g e n e s[ 72]. Nevertheless, these
data are not totally contradictory since they can be explained
by the design of siRNA nucleotidic sequences. When we did
a more in-depth analysis of both studies, we found that the
design of siRNAs is directed to diﬀerent sequences of E6
oncogene. This suggests a silencing eﬀect that is dependent
on the complementary position of the bases between siRNAs
and mRNA. Therefore, the silencing of the HPV E6-E7
bicistronic transcript is dependent on the design of siRNA
sequences for HPV E6 and E7 oncogenes. In addition, when
analyzing the eﬀect of HPV18 E6-E7 bicistron silencing,
it was seen that administration of siRNAs speciﬁc for E7
induces silencing of both E6/E7 oncogenes, whereas siRNAs
for E6 only inhibit E6 expression but do not have eﬀects on
E7 expression [75]. In the analysis of the design of siRNA
sequences for E7, we observed that the complementarity of
baseswiththecorrespondingmRNAoccursinapositionthat
aﬀects the expression of the E6-E7 bicistron; nevertheless,
siRNAs for E6 are complementary with mRNA in a sequence
that does not inﬂuence the silencing of the E6-E7 bicistronic
transcript. Again, this evidence supports the fact that the
silencing of HPV E6-E7 bicistron expression is dependent
on the design of the siRNA sequences and suggests that the
alternative splicing of HPV E6/E7 oncogenes precedes the
silencing by siRNAs. Additionally, this same study analyzed
the functionality of siRNAs for E6/E7 and demonstrated the
induction of expression in p53, p16, p21, p27, and in the
hypophosphorylated isoform of pRb, the silencing of cyclin
A gene, and the induction of apoptosis in human cancer
cells. This evidence supports the fact that viral oncoproteins
can have antiapoptotic properties by their inﬂuence on p53
protein function and when these oncogenes are silenced with
siRNAs, p53 recovers the cellular cycle control functions and
apoptosis[76].Thus,E6oncoproteinmayhaveanimportant
impact on other components of the apoptosis regulatory
machinery. The high risk HPV E6 oncoproteins induce
the proteolytic inactivation of certain proapoptotic proteins
such as p53 [77], Bak [78], FADD [79], procaspase-8 [80],
or c-Myc [81, 82]. In human keratinocytes immortalized
by E6, low levels of apoptosis as compared to the non-
immortalized control cells were observed after CD95 (Fas)
agonist treatment [79]. Interestingly, in addition to p53 and
p21, protein levels of antiapoptotic proteins Bcl-2 and Flip
were reduced. Proteosomal inhibition increased the suscep-
tibility of E6 expressing cells to CD95-mediated apoptosis.
In addition, several studies have examined the sensitivity of
cells expressing E6 to TNF. HPV-16 E6 was shown to bind
to the C-terminal end TNF receptor 1 (TNF R1) and protect
cells from TNF-induced apoptosis in mouse ﬁbroblasts and
human histiocyte/monocyte and osteosarcoma cells [83, 84].
E6 binding to TNF R1 interfered with the Fas pathway.
Furthermore, use of an inducible E6 expression system
demonstrated that this protection is dose dependent, with
higher levels of E6 leading to greater protection. Although E6
suppresses activation of both caspase 3 and caspase 8, it does
not aﬀect apoptotic signaling through the mitochondrial
pathway. Mammalian two hybrid are demonstrated that E6
binds directly to the death eﬀectors domain of Fas-associated
death domain (FADD) and to protect cells from Fas-induced
apoptosis. In addition, binding to E6 leads to degradation
of FADD, with the loss of cellular FADD proportional
to the amount of E6 expressed. These results support a
model in which E6-mediated degradation of FADD prevents
transmission of apoptotic signals via the Fas pathway [85].
3.6. Chemotherapeutical Agents and siRNAs for HPV E6 and
E7. Although we know the eﬀect of diﬀerent chemothera-
peutical drugs on the expression of p53 protein in human6 Journal of Oncology
Table 1
HPV oncogenes siRNA design Biological eﬀects References
HPV16 E6 and E7 Synthetic siRNA Silencing of HPV16 E6 and E7, p53, p21 and pRb expression.
Apoptosis induction in vitro. [72]
HPV16 E6 Synthetic siRNA
Silencing of HPV16 E and E7, p53, p21 and pRb expression.
Cellular proliferation inhibition in vitro. Tumor growth inhibition
in vivo.
[73]
HPV18 E6 Synthetic siRNA Silencing of HPV16 E6, p53, p21, and pRb expression. Apoptosis
induction in vitro. [74]
HPV16 E7 Synthetic siRNA in
bio-adhesive gels Silencing of HPV16 E7. Apoptosis induction in vitro.[ 87]
H P V 1 8E 6a n dE 7 Synthetic siRNA with
chemotherapy
Silencing of HPV18 E6 and E7, as well as p53 expression.
Cytotoxicity decrease in vitro. [94]
HPV18 E6 siRNA in lentivirus with
chemotherapy
Silencing of HPV18 E6 and E7, as well as p53 expression.
Cytotoxicity decrease in vitro. [86]
H P V 1 6E 6a n dE 7 Synthetic siRNA in
liposomes
Silencing of HPV16 E6 and E7. Apoptosis induction in vitro.
Tumor growth inhibition in vivo. [88]
H P V 1 8E 6a n dE 7 siRNA with
atelocollagen
Silencing of HPV18 E6 and E7, as well as p53 and pRb expression.
Cellular senescence induction in vitro. Tumor growth inhibition in
vivo.
[89]
HPV18 E6 and E7 Synthetic siRNA Silencing of HPV18 E6 and E7 and cyclin A gene, as well as p53,
pRb, p16, p21, and p27 expression. Apoptosis induction in vitro. [75]
H P V 1 8E 6a n dE 7 siRNA in pSUPER
plasmid
Silencing of HPV16 E6 and E7, as well as p53 and pRb expression.
Transcriptome expression analysis of cancer cells. [91]
H P V 1 6E 6a n dE 7 siRNA in psiCheck 2
plasmid
Silencing of HPV16 E6 and E7, as well as p53 and p21 expression.
Cellular senescence induction in vitro. Tumor growth inhibition in
vivo.
[95]
HPV16 E7 siRNA in pSIRE-DNR
plasmid
Silencing of HPV E6 and E7, as well as p53, p21 and pRb
expression. Apoptosis induction in vitro. [96]
High risk HPV E6
and E7 siRNA in lentivirus
Silencing of HPV16 E6 and E7. p53 and p21 expression. Apoptosis
induction in vitro and in vivo.H i g he ﬃciency of infection of
proliferation cells and quiescent cells.
[90]
H P V 1 6E 6a n dE 7 siRNA in pSilencer
1.0U6-plasmid
Silencing of HPV16 E6 and E7. p53 and pRb expression. Cellular
proliferation inhibition. Autophagic and apoptosis induction of
tumor cells in vivo.
[97]
tumoral cervical cells, we do not know if there is an
association between the activation of gene p53, the cytotoxic
eﬀect of drugs, and the silencing of HPV oncogenes with
siRNAs. Thus, diﬀerent groups have analyzed the expression
ofp53proteininHeLacells(HPV18+)bytheadministration
of siRNAs for the HPV18 E6 oncogene, combined with
treatment by carboplatin, cisplatin, doxorubicin, etoposide,
gemcitabine, mitomicine, mitoxantrone, oxaliplatin, pacli-
taxel, and topotecan [76]. In this study, the silencing of
H P V 1 8E 6 / E 7o n c o g e n e sw a so b s e rv e d ,a sw e l la sa ni n c r e a s e
in p53 protein expression and changes in cytotoxicity that
were dependent on the nature of each chemotherapeutical
compound. Also, another group demonstrated, using HeLa
cells, that the administration of speciﬁc siRNAs for HPV18
E6 generated in lentivirus, combined with cisplatin, the drug
most frequently used in the treatment of advanced CC,
produces the silencing of HPV18 E6 and E7 oncogenes,
an increase in p53 expression and death of cancer cells
by cellular senescence [86]. This evidence suggests that the
silencing of HPV E6/E7 oncogenes by siRNAs can increase
the cells sensitivity to the cytotoxic eﬀects of drugs and that
the combined treatment may have a synergistic eﬀect in
decreasingtheresistancetochemotherapeuticaldrugs,which
is an advantage for treatment.
3.7. siRNAs Transporting Molecules for HPV E6/E7. In the
evaluation of the biological eﬀects of siRNAs, in vitro as
well as in vivo, protocols for the administration of synthetic
siRNAs have been developed, for HPV E6/E7 oncogenes,
where these molecules are coupled with liposomes as trans-
port vehicles [87]. In these studies, it has been shown in
CaSki (HPV16+) cells that when siRNAs for HPV16 E6/E7
are administered, silencing of both oncogenes is induced and
the cancer cells die by apoptosis. With this same system, and
through the development of a murine tumor model with
CaSki cells, the eﬀects of siRNAs for E6 have been evaluated
and the silencing of the viral oncogene has been determined,
as well as the induction of apoptosis of tumor cells and
a signiﬁcant inhibition of the growth of the tumoral mass
in vivo [87]. Although these ﬁndings are signiﬁcant, when
synthetic siRNAs are used and administered by lipofectionJournal of Oncology 7
to mammalian cells, a potential problem that appears
is the cleavage of siRNAs by the action of endogenous
cellular endonucleases. An alternative design to protect
the siRNAs from this cleavage is the synthesis of siRNAs
with chemical modiﬁcations; however, this may induce
undesirable collateral eﬀects. Another problem that arises in
the systemic administration of siRNAs is that we do not have
ad o s ed e p e n d e n te ﬀect on target organs. Thus, in order to
overcome these methodological inconveniences, it has been
reported that the speciﬁc siRNAs for HPV oncogenes may be
administeredinaliposomebasedsystemcontainedinbiogels
[88]. The combination of adhesive biogels and liposomes
containing siRNAs for the HPV16 E7 oncogene has resulted
in the speciﬁc silencing of E7 and the induction of apoptosis
of cancerous cells in vitro. In addition, the use of atelocolla-
gen as a vehicle to administer the siRNAs for HPV18 E6 and
E7, in vitro as well as in vivo, has also been reported [89].
In this study, it has been observed that siRNAs silence E6/E7
oncogenes expression, inhibit cellular proliferation, induce
the expression of the hypophosphorylated isoform of pRB,
and induce death of cancerous cells by cellular senescence.
In this same system, it was also demonstrated that the
administration of siRNAs for HPV18 E6/E7, attached to
atelocollagen, inhibits the growth of the tumor mass in a
murinetumoralmodel[89].Althoughthesilencingeﬀectsof
synthetic siRNAs are evident, the half life of these molecules
after their administration is relatively short, even when they
are attached to transporting molecules; this limits their
application in preclinical or clinical trials. Besides this, the
real application of siRNAs for high-risk HPV oncogenes in
clinical phase studies, requires a better understanding of the
development of highly speciﬁc siRNAs and greater eﬃciency
in the in vivo liberation systems. In this sense, protocols
have been developed for the generation of lentiviruses as
molecular liberation vectors for speciﬁc siRNAs for high-
risk HPV E6 and E7 oncogenes, as well as for their stable
transfection and transduction in human CC cells. The
biological eﬀects of silencing with siRNAs, in vitro as well as
in vivo models, are being evaluated [90].
3.8. Transcriptome Regulation by the Eﬀect of siRNAs for
HPV E6/E7. Another aspect of the silencing of HPV E6/E7
oncogenes that has been studied, using siRNAs, is the eﬀect
it has on transcriptome regulation of human tumor cervical
cells. In 2007, Kuner et al. [91] analyzed the transcriptome of
HeLa cells and cervical cells from patient biopsies, inducing
the silencing of HPV 18 E6 and E7 with siRNAs generated
in the silencing plasmid of pSUPER. In this study, 360
cellulargeneswereidentiﬁedwhichhadanegativeregulation
and 288 genes with positive regulation due to the eﬀect
of siRNAs for E6/E7. Most of these genes are involved in
relevant biological processes during the development of the
tumor cell, such as: apoptosis control, regulation of the
cell cycle, formation of the mitotic spindle, processing of
mRNA by splicing, metabolism, DNA replication and repair,
nuclear transport, cell proliferation, and gene regulation by
c-Myc. These ﬁndings complement previous studies where
the expression of HPV E2 protein has been analyzed. This
protein inhibits HPV E6/E7 expression, and the expression
of the transcriptome in human tumor cervical cells. The
potential of this type of studies lies in the fact that the basic
cell pathways for viral transformation may be identiﬁed,
which may be targets for the development of therapeutical
strategies. Also, new molecular biomarkers may be found
for diagnosis and prognosis of CC. An example of these
biomarkers is the enhancer of zeste homolog 2 (EZH2),
which is repressed by the inhibition of E6/E7 by siRNAs.
These data suggest that this biomarker is active in CC cells
transformed by HPV [91]. Thus, the information generated
by the study of the transcriptome of CC cells, using siRNAs
for HPV oncogenes, may contribute to the diagnosis prog-
nosis and treatment of this neoplasia. It has been previously
demonstrated that silencing E6 and E7 has eﬀects on several
cellular targets. For example, a connection between onco-
genic HPVs and C-MYC during the transformation process
has been previously discussed. For example, insertion of
HPVs close to the MYC locus is observed in about 10%
of HPV positive genital cancers, and it has been speculated
that the HPV transcriptional control region may induce
overexpression of the nearby MYC gene [92]. Ectopically
expressed E6 has been reported to stimulate the C-MYC
promoter, and E6 and/or E7 can increase C-MYC expression
under certain experimental conditions [93]. The data on
transcriptome regulation by siRNA, for E6 and E7, would be
consistent with the idea that the viral E6/E7 genes can either
directly or indirectly activate C-MYC expression; this may be
an alternative mechanism for inducing downstream C-MYC
targets during HPV-associated carcinogenesis.
4. Conclusions
Cervical lesions caused by HPV persistent infection can be
removed naturally by the host immune response, and only a
small percentage may progress to cancer, thus, the immune
response is essential for the control of precursor lesions
and CC. Therefore, to know the molecular mechanisms
and potential targets for blocking HPV-induced, lesion
developmentisofhighrelevance,because80%percentofCC
cases are in developing countries. HPV prophylactic vaccines
and constructionof the sanitary structureare very expensive;
therefore, to develop techniques base on genomic approach
will be very useful for CC therapy. The relevance of this
approach will be better appreciated once it is applied in
clinical protocols.
Thecorrectionofimmune-activating signals,eradication
of inhibitory factors, and the evasion from newly developed
immunoresistant tumor phenotypes need to be simultane-
ously considered.
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